Innostar succefully assisted Signet Therapeutics in the IND approval by U.S. FDA of the world's first targeted drug for the treatment of diffuse gastric cancer
2024-07-19
Signet Therapeutics, InnoStar's partner in excellence, has announced that its proprietary pipeline of the world's first targeted drug for the treatment of diffuse gastric cancer has been approved by the U.S. FDA for the clinical trial.
InnoStar is proud to have participated in the development process of this excellent project, providing the full suite of toxicological assessment and ADME services, in strict compliance with FDA guidelines for GLP and in compliance with FDA standards. A series of scientific, systematic and high-quality trial programs have been formulated to support the R&D process of Signet Therapeutics and jointly promote the project smoothly.
